- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07262255
WATCHMAN FLX Pro Europeiskt register
The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Aarhus, Danmark, 8200
- Aarhus University Hospital
-
Copenhagen, Danmark, 2100
- Rigshospitalet Copenhagen
-
-
-
-
-
Catania, Italien, 95123
- Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco
-
Milan, Italien, 20138
- Centro Cardiologico Monzino
-
Verona, Italien, 37126
- Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Poznan, Polen, 61-848
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
-
-
-
-
Basel, Schweiz, 4031
- University Hospital Basel
-
Bern, Schweiz, CH-3010
- INSELSPITAL - Universitätsspital Bern
-
-
-
-
-
León, Spanien, 24071
- Hospital de Leon
-
Pamplona, Spanien, 31008
- Clinica Universidad de Navarra
-
Pontevedra, Spanien, 36001
- Complejo Hospitalario Universitario de Pontevedra
-
Pontevedra, Spanien, 36001
- Complejo Hospitalario de Pontevedra
-
Salamanca, Spanien, 37007
- Hospital Clinico Salamanca
-
-
-
-
-
Bad Oeynhausen, Tyskland, 32545
- Herz-und Diabeteszentrum Nordrhein-Westfalen
-
Berlin, Tyskland, 12203
- Charite, Campus Benjamin Franklin
-
Erfurt, Tyskland, 99097
- Kath Krankenhaus St Johann Nepomuk
-
Hamburg, Tyskland, 22763
- Asklepios Klinik Altona
-
Hamburg, Tyskland, 20099
- Asklepios Klinik Saint Georg
-
Hamburg, Tyskland, 22417
- Asklepios Klinik Nord Heidberg
-
Lübeck, Tyskland, 23582
- Universitaetsklinikum Schleswig-Holstein
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Hospital
Beskrivning
Inclusion Criteria:
- Subject is attempted to be treated with the WATCHMAN FLX™ Pro LAAC device.
- Subject has non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve) and is clinically indicated for a WATCHMAN FLX™ Pro LAAC device, per the Instructions for Use (IFU).
- Subject or legal representative who are willing and capable of providing informed consent.
- Subject is able and willing to return for required follow-up visits and examinations.
- Subject whose age is 18 years or above, or who is of legal age to give informed consent specific to state and national law.
Exclusion Criteria:
- Subject has a documented life expectancy of less than 12 months.
- Subject who is currently enrolled in another investigational study or registry except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments.
- Intracardiac thrombus is present.
- An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
- The LAA anatomy will not accommodate a Closure Device.
- Subject has a known hypersensitivity or contraindications according to IFU.
- Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
WATCHMAN FLX Pro
This arm is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. Approximately 300 patients undergo the LAAC procedure in conjunction with the use of the VersaCross Connect™ LAAC Access Solution. |
The WATCHMAN FLX Pro LAAC Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in adult patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy. The VersaCross Connect™ LAAC Access Solution is indicated for the percutaneous introduction of various types of cardiovascular catheters and guidewires to all heart chambers, including the left atrium via transseptal perforation / puncture. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants with a safety event treated with the WATCHMAN FLX Pro
Tidsram: Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
Proportion of subjects with one or more of the following events between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair, or other major endovascular repair. Percutaneous catheter drainage of pericardial effusions, snaring of an embolized device, thrombin injection to treat femoral pseudoaneurysm and minor nonsurgical treatments of access site complications are excluded from this endpoint. |
Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
|
Number of participants with a safety event treated with the VersaCross Connect™ LAAC Access Solution
Tidsram: Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
Proportion of subjects with one or more of the following events between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later: For all enrolled subjects, who had an attempt to insert the VersaCross Connect™ LAAC Access Solution device, the composite rate of all-cause death, all stroke, systemic embolism, pericardial effusion resulting in interventions*, and ISTH major bleeding. *Pericardial effusion/tamponade requiring pericardiocentesis or surgery to treat |
Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
|
Number of participants with a successful VersaCross Connect™ LAAC Access Solution treatment
Tidsram: Completion of transseptal puncture
|
VersaCross Connect™ LAAC Access Solution acute procedural success: Acute Procedural Success is defined as transseptal puncture success (VersaCross RF-wire crossing into left atrium). |
Completion of transseptal puncture
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Arian Sultan, Prof. MD, Asklepios Klinik Saint Georg
- Huvudutredare: Marek Grygier, Prof. MD, PHD, Uniwersytecki Szpital Kliniczny w Poznaniu
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- S2603
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .